• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

4.360 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Iovance Biotherapeutics, Inc. - Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
12 Health Care Stocks Moving In Monday's Intraday Session ↗
December 05, 2022
 
Via Benzinga
News headline image
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points ↗
December 05, 2022
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday. 
Via Benzinga
News headline image
Iovance Biotherapeutics Stock Is Surging: Here's Why ↗
December 05, 2022
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
December 05, 2022
 
Via Benzinga
News headline image
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying ↗
December 05, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics ↗
November 21, 2022
 
Via Benzinga
News headline image
Recap: Iovance Biotherapeutics Q3 Earnings ↗
November 03, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Expert Ratings for Iovance Biotherapeutics ↗
August 05, 2022
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: 
Via Benzinga
News headline image
7 Analysts Have This to Say About Iovance Biotherapeutics ↗
July 01, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Iovance Biotherapeutics to Present at Upcoming Conferences
November 30, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock ↗
November 21, 2022
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on... 
Via Benzinga
News headline image
Why Iovance Biotherapeutics Is Crashing Today ↗
November 18, 2022
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy. 
Via The Motley Fool
News headline image
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate ↗
November 18, 2022
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
November 18, 2022
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
November 18, 2022
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning! 
Via InvestorPlace
News headline image
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 18, 2022
BLA Submission Ongoing with U.S. Food and Drug Administration 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗
November 15, 2022
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
News headline image
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
November 03, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Preview: Iovance Biotherapeutics's Earnings ↗
November 02, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
October 24, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022 ↗
October 31, 2022
Upgrades 
Via Benzinga
News headline image
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
October 10, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
5 Top Stocks Cathie Wood Is Selling This Week ↗
August 26, 2022
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
August 25, 2022
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
August 17, 2022
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Iovance Biotherapeutics: Q2 Earnings Insights ↗
August 04, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
July 27, 2022
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
17 18 19 20 21 22 23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap